Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia secondary to or associated with non-dialysis dependent chronic kidney disease anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.

Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia secondary to or associated with non-dialysis dependent chronic kidney disease anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.

The present invention is directed to compositions and formulations for hair growth. The non-aqueous, preservative-free formulations are useful for the growth of hair, eyebrows and eyelash in a variety of setting. Also provided herein are non-aqueous, preservative-free formulations and methods for the treatment of dry-eye and related symptoms.

The present invention is directed to compositions and formulations for hair growth. The non-aqueous, preservative-free formulations are useful for the growth of hair, eyebrows and eyelash in a variety of setting. Also provided herein are non-aqueous, preservative-free formulations and methods for the treatment of dry-eye and related symptoms.

N-palmitoylethanolamide (PEA) is used in combination with docosahexaenoic acid (DHA) in the treatment of autism spectrum disorder and other depressive syndromes. In particular, N-palmitoylethanolamide (PEA) is used in combination with docosahexaenoic acid (DHA) in the treatment of diseases having decreased endogenous levels of allopregnanolone.

N-palmitoylethanolamide (PEA) is used in combination with docosahexaenoic acid (DHA) in the treatment of autism spectrum disorder and other depressive syndromes. In particular, N-palmitoylethanolamide (PEA) is used in combination with docosahexaenoic acid (DHA) in the treatment of diseases having decreased endogenous levels of allopregnanolone.

Provided is a pharmaceutical agent for effective prophylaxis and/or treatment of a pathological condition with decreased lung compliance. The pharmaceutical agent for prophylaxis and/or treatment of a pathological condition with decreased lung compliance is characterized by having a polyamine. The polyamine includes at least one of spermine (Spm), spermidine (Spd), and putrescine (Put). The pharmaceutical agent improves lung compliance and ameliorates gas exchange dysfunction, and therefore, can ameliorate pathological conditions such as acute respiratory distress syndrome (ARDS), acute lung injury (ALI), lung diseases caused by dysfunctional endogenous pulmonary alveolar surfactant, multiple organ dysfunction syndrome (MODS), and cardiogenic pulmonary edema.

Provided is a pharmaceutical agent for effective prophylaxis and/or treatment of a pathological condition with decreased lung compliance. The pharmaceutical agent for prophylaxis and/or treatment of a pathological condition with decreased lung compliance is characterized by having a polyamine. The polyamine includes at least one of spermine (Spm), spermidine (Spd), and putrescine (Put). The pharmaceutical agent improves lung compliance and ameliorates gas exchange dysfunction, and therefore, can ameliorate pathological conditions such as acute respiratory distress syndrome (ARDS), acute lung injury (ALI), lung diseases caused by dysfunctional endogenous pulmonary alveolar surfactant, multiple organ dysfunction syndrome (MODS), and cardiogenic pulmonary edema.

Provided are nutritional compositions having a non-soy-based plant protein component that includes chia proteins, hemp proteins, or combinations thereof. Further disclosed are nutritional composition having a non-soy-based plant protein source that includes chia proteins in combination with hemp proteins and free amino acids. The nutritional compositions disclosed are suitable for administration to human subjects, such as infants.

Provided are nutritional compositions having a non-soy-based plant protein component that includes chia proteins, hemp proteins, or combinations thereof. Further disclosed are nutritional composition having a non-soy-based plant protein source that includes chia proteins in combination with hemp proteins and free amino acids. The nutritional compositions disclosed are suitable for administration to human subjects, such as infants.